Abstract
In recent years, two topical calcineurin inhibitors have emerged as effective alternatives to corticosteroids for the treatment of atopic dermatitis. Decisions regarding first line therapy between pimecrolimus and tacrolimus are often based on anecdotal evidence. Herein, we review the current evidence supporting the use of pimecrolimus and tacrolimus in atopic dermatitis as well as key differences in safety, tolerability, and cost between the drugs.
Cite
CITATION STYLE
Crissinger, A., & Nguyen, N. V. (2014). The Use of Topical Calcineurin Inhibitors in Atopic Dermatitis. The Open Dermatology Journal, 8(1), 12–17. https://doi.org/10.2174/1874372201408010012
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.